StreetAlpha.app
Home › Stocks › PMVP

PMV Pharmaceuticals, Inc. (PMVP)

$0.88
▼ −33.13%
LAST CLOSE · NOV 20

PMV Pharmaceuticals develops oral small molecule cancer drugs that target mutations in the p53 protein. It last closed at $0.88 on Nov 20, down 33.13% on the day. The next earnings report for PMVP is expected around Fri, Mar 5, 2027. For the quarter ended Sep 2026, PMVP reported EPS of -$0.52. Over its last 8 reports the stock moved an average of 3.8% the session after earnings.

AI Auto Pilots
Is PMVP in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PMVP.

Key Stats

Last 12 months
Results
Net income
−$88.5M
EPS (diluted)
−$1.56
Free cash flow
−$69.6M
Valuation
Market cap
$66.2M
75.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$20.0M
At Sep 30
Shareholder equity
$57.1M
Shares outstanding
75.5M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$57.8M−$57.8MFY2021FY2022: −$73.3M−$73.3MFY2022FY2023: −$69.0M−$69.0MFY2023FY2024: −$58.7M−$58.7MFY2024FY2025: −$77.7M−$77.7MFY2025

From PMVP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Mar 5
Estimated date · Time not announced
Reported EPS
-$0.52
Quarter ended Sep 2026
Year ago EPS
-$0.40
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.45Dec '24Mar 2025: -$0.34Mar '25Jun 2025: -$0.41Jun '25Sep 2025: -$0.40Sep '25Dec 2025: -$0.34Dec '25Mar 2026: -$0.34Mar '26Jun 2026: -$0.34Jun '26Sep 2026: -$0.52Sep '26Latest -$0.52
Revenue by quarter
Not enough quarters on file yet.
How PMVP moved after its last 8 reports
Average move the session after a report ±3.8%
Nov 10, 2026Time not announced−2.4%
Aug 14, 2026Time not announced+3.7%
May 12, 2026Time not announced+2.2%
Mar 6, 2026Time not announced+7.2%
Nov 12, 2025Time not announced+6.8%
Aug 7, 2025Time not announced−4.6%
May 9, 2025Time not announced−0.1%
Mar 3, 2025Time not announced−3.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PMVPStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PMVP
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PMVP

Technical Analysis

PMVP · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 43% below its 20 day and 56% below its 50 day average. It is 50% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), near oversold. The nearest support is the 52 week low at $0.66, and the nearest resistance the Pivot at $0.96.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 16.8%/day
Key levels
$1.9152 week high+117.0%
$1.3750 day average+55.7%
$1.31100 day average+48.9%
$1.31200 day average+48.9%
$1.28Swing high (Jun 2)+45.5%
$1.26Pivot R1+43.2%
$1.2520 day average+42.0%
$0.96Pivot+9.1%
$0.88Last close
$0.6652 week low−25.0%
$0.58Pivot S1−34.1%
Indicators
RSI (14)31.45Weak, oversold below 30Neutral
MACD-0.06Below its signal lineBearish
Stochastic44.4Middle of its rangeNeutral
ADX (14)24.7Weak trend
Williams %R-72.3Oversold below −80, overbought above −20Neutral
CCI (20)-321.1Oversold below −100, overbought above 100Oversold
Rate of change−30.5%Change over 10 sessionsBearish
ATR (14)$0.15Typical daily range, 16.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PMVP

What happened before

See how PMVP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PMVP usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PMVP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PMVPHow many large options trades hit PMVP, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

PMVP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲32 buying vs 20 selling
  • ▲Held by funds +29.0 pts
  • ▲Funds holding +1
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6564+1.6%
In funds' top 10220.0%
Held by funds74.8%45.8%+29.0 pts
New / increased9 / 234 / 15+68.4%
Reduced / sold out12 / 821 / 9−33.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PMVP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PMVP Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 23, 2025OrbiMed Capital GP V LLC10% ownerSale1,000,000$1.52$1.5M
Sep 10, 2025Orbimed Advisors LLC10% ownerSale500,000$1.80$900K
Jul 1, 2025David Henry MackPresident and CEOSale58,411$1.06$62K
Jul 1, 2025Michael CarulliCFOSale28,249$1.06$30K
Jul 1, 2025Deepika JalotaChief Development OfficerSale33,065$1.06$35K
Jul 1, 2025Robert TicktinGeneral Counsel & COOSale23,151$1.06$25K
Every insider buy and sale for PMVP over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PMVP insider trades →

From SEC Form 4 filings by PMVP's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PMVP is in one of them and how their past PMVP trades turned out.

PMVP in the AI portfolios
Loading…

PMVP News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PMVP in an article yet. Here's the latest on the wider market.

PMVP in the news

About PMV Pharmaceuticals

PMV Pharmaceuticals is a cancer drug developer based in Princeton, New Jersey. It develops oral small molecule medicines that aim to restore normal function to mutant p53, a protein that helps stop cancer growth when it works properly. Its lead product candidate, rezatapopt, targets a specific p53 mutation found in several solid tumors, including some ovarian, lung and colorectal cancers. The company's therapies are intended for cancer patients whose tumors carry these mutations.

Headquarters
Princeton, NJ